Target intelligence / Profile preview

Amino acid transporter heavy chain SLC3A2 (SLC3A2)

Target
SLC3A2
Molecular classification
Transporter, Receptor, Other
01

Overview

Amino acid transporter heavy chain SLC3A2 (also known as CD98hc or 4F2hc) is a type II transmembrane glycoprotein that plays a critical role in cellular metabolism and integrin-dependent signaling. It functions primarily as a chaperone, forming disulfide-linked heterodimers with various light chains of the SLC7 family (such as LAT1, LAT2, and xCT) to facilitate their trafficking to the plasma membrane and stabilize their amino acid transport activity. Beyond its role in nutrient uptake, SLC3A2 interacts with integrins to regulate cell adhesion, migration, survival, and proliferation. It is highly overexpressed in numerous hematological and solid malignancies, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC), where it supports the high metabolic demands of rapidly dividing tumor cells. Consequently, SLC3A2 has emerged as a promising therapeutic target, with monoclonal antibodies (such as IGN523 and KHK2898), antibody-drug conjugates (ADCs), and CAR-T therapies being developed to inhibit its transport function, disrupt integrin signaling, and induce antibody-dependent cellular cytotoxicity (ADCC).

Other names
CD98 heavy chainCD98hc4F2 cell-surface antigen heavy chain4F2hcSolute carrier family 3 member 2Lymphocyte activation antigen 4F2 large subunit4F2 heavy chain antigenMDU1NACAE
02

Mechanism of action

Antibody-dependent cellular cytotoxicity (ADCC), inhibition of amino acid transport, lysosomal membrane permeabilization, apoptosis induction, and disruption of heterodimeric transporter complexes

03

Biological functions

Amino acid transportCell proliferationCell survivalCell migrationIntegrin signalingmTORC1 activationMetabolic reprogrammingOther
04

Disease associations

CancerInflammationInfectionOther
05

Safety considerations

On-target off-tumor toxicity due to expression in normal tissues (e.g., kidney, testis, cerebellum, activated immune cells)Infusional toxicityPotential impairment of normal amino acid transport in healthy tissues
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

SLC3A2 expression levelCD98 expression levelCD98 receptor occupancy

Beyond the preview

Go deeper on Amino acid transporter heavy chain SLC3A2 (SLC3A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amino acid transporter heavy chain SLC3A2 (SLC3A2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call